Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rondecabtagene autoleucel vs CD19 CAR T in relapsed/refractory large B-cell lymphoma
NCT07188558Phase 3Recruiting
- Sponsor
- Lyell Immunopharma
- Start
- Jan 2026
- Primary completion
- Dec 2029
- Modality
- CAR-T Cells
- Countries
- 3
01
Overview
A Phase 3 trial of rondecabtagene autoleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Lyell Immunopharma. Started Jan 2026; status: recruiting.
02
Drugs
rondecabtagene autoleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07188558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07188558.